BMC Microbiology                                                                                                                         BioMed Central



Research article                                                                                                                       Open Access
Dxr essential Mycobacterium tuberculosis fosmidomycin
resistance lack uptake
Amanda C Brown Tanya Parish*

Address: Institute Cell Molecular Science, Barts London School Medicine Dentistry, London, UK
Email: Amanda C Brown - c.brown@qmul.ac.uk; Tanya Parish* - t.parish@qmul.ac.uk
* Corresponding author




Published: 20 2008                                                        Received: 10 September 2007
                                                                              Accepted: 20 2008
BMC Microbiology 2008, 8:78   doi:10.1186/1471-2180-8-78 article available  http://www.biomedcentral.com/1471-2180/8/78
© 2008 Brown Parish; licensee BioMed Central  Open Access article distributed terms Creative Commons Attribution License (http://creativecommons.org/licenses 2.0), permits unrestricted use, distribution, reproduction medium, provided original work properly cited.




                 Abstract
                 Fosmidomycin phosphonic antibiotic inhibits 1-deoxy-D-xylulose 5-phosphate
                 reductoisomerase (Dxr), committed step non-mevalonate pathway isoprenoid
                 biosynthesis. Mycobacterium tuberculosis Dxr encoded Rv2870c, antibiotic
                 shown inhibit recombinant enzyme [1], mycobacteria intrinsically resistant                  fosmidomycin cell level. Fosmidomycin hydrophilic molecule bacteria
                 uptake active process involving cAMP dependent glycerol-3-phosphate transporter
                 (GlpT). fact glpT homologue M. tuberculosis genome highly
                 impervious nature hydrophobic mycobacterial cell wall suggests resistance                  lack cellular penetration.
                 Results: demonstrated dxr (Rv2780c) essential gene M. tuberculosis,                  delete chromosomal copy unless second functional copy provided integrating
                 vector. confirmed intracellular target fosmidomycin essential                  sensitive. looked uptake fosmidomycin mycobacterial species, slow-
                 growing pathogenic M. tuberculosis fast-growing, saprophytic Mycobacterium smegmatis;                  species resistant fosmidomycin high level. Fosmidomycin accumulated intra-
                 cellularly M. tuberculosis M. smegmatis remained extra-cellular medium. contrast,
                 fosmidomycin uptake confirmed sensitive organism, Escherichia coli. established                  lack intra-cellular accumulation efflux, efflux pump inhibitors                  effect fosmidomycin resistance. Finally, demonstrated fosmidomycin modified
                 mycobacterial cells extracts remained fully functional state.
                 Conclusion: Taken  data demonstrate fosmidomycin resistance M.
                 tuberculosis M. smegmatis results lack penetration antibiotic site                  sensitive target.




Background                                                                    terium tuberculosis,  main causative agent human mycobacteria contain number important patho-                         tuberculosis), resulting million deaths gens infect animals humans. World                          year [2]. Currently available vaccine live,
Health Organisation   estimated mil-                       attenuated Mycobacterium bovis Calmette-Guerin (BCG)
lion humans annum newly infected Mycobac-                        strain;  BCG does offer complete immunity,

                                                                                                                                         Page 1 9
                                                                                                                 (page number citation purposes)
 BMC Microbiology 2008, 8:78                                                   http://www.biomedcentral.com/1471-2180/8/78


 protection highly variable wide range         Fosmidomycin (sodium hydrogen 3-(N-hydroxyfoma-
social, economic environmental factors. Opportunis-          mido)propylphosphonate) phosphonate antibiotic
tic mycobacterial pathogens identified caus-        inhibits enzymes DOXP pathway
ing disseminated disease HIV-infected            – DOXP reductoisomerase (Dxr) [10].  anti-
immuno-compromised individuals. addition                    microbial activity shown limited Gram-
number diseases, including leprosy          negative species, fosmidomycin effective
Buruli ulcer, caused mycobacteria.          Gram-positive cocci anaerobic species [11,12].
infections increase  effective ther-     Escherichia coli, fosmidomycin transported apy exists diseases, increase multi-     cell glycerol-3-phosphate transporter, GlpT, drug resistance strains jeopardises ability treat         glpT deletion mutants fosmidomycin resistant [13].  Current research trends focused produc-         fosmidomycin resistance gene (fsr) identi-
tion improved vaccine, identification new drug          fied bacteria including E. coli Brucella spp.
targets, development new anti-mycobacterials.         [14,15]. Fsr member family permeases, suggest- activities benefited greatly avail-   ing resistance results rapid efflux drug
ability complete genome sequence M. tuberculosis       cell. Fosmidomycin currently considered
[3].                                                             treatment malaria [16-18].
 need new antibiotics effective myco-         Mycobacteria, including M. tuberculosis, highly resist-
bacteria greater. addition search     ant fosmidomycin cell level, new antibiotics, renewed exam-        recombinant M. tuberculosis Dxr sensitive fosmid-
ining existing compounds efficacy anti-mycobacte-         omycin, mechanism resistance unknown [1].
rial agents. Mycobacteria relatively antibiotic resistant    study, characterized basis intrinsic susceptible commonly used antibi-            resistance M. tuberculosis M. smegmatis fosmid-
otic groups, penicillins. intrinsic resist-     omycin. demonstrated dxr gene essential ance attributed largely nature            M. tuberculosis, confirming organism sensi-
mycobacterial cell wall, rich long-chain fatty       tive vulnerable target. investigated uptake fos-
acids including C60 C90 mycolic acids,          midomycin mycobacteria E. coli using bioassay
covalently linked arabinogalactan-peptidogylcan           fosmidomycin. Efflux pump inhibitors used layer. Porins, (water-rich channel proteins allow          assess role efflux mediating fosmidomycin resist-
hydrophilic molecules enter cell diffusion),      ance. Inactivation fosmidomycin mycobacterial cells
rare mycobacteria [4] function         cell-free extracts tested. considerably reduced rate comparison porins Gram-negative bacteria Mycobacterium smegmatis [5-7].         Results antibiotic resistance physical     Essentiality Dxr
properties cell wall forming impermeable barrier       interested determining basis mycobac-
[8], drug inactivation assumed       terial resistance fosmidomycin. target fosmid- bacteria susceptible intracellular targets,     omycin enzyme Dxr (DOXP reductoisomerase, drugs modified allow cellular entry     Rv2870c), committed step non-mevalonate effective.                                          pathway isoprenoid biosynthesis. M. tuberculosis Dxr
                                                                 expressed recombinant protein read-
Isopentenyl disphosphate (IPP) common precursor          ily inhibited fosmidomycin [1], indicating resist- biosynthesis isoprenoid compounds.               ance lack susceptible target. includes polyprenyl phosphate, involved          possibility account lack cell sensitivity
synthesis covalently linked peptidoglycan-arabi-          Dxr required mycobacterial growth. nogalactan-mycolic acid complex, lipomannan                  non-mevalonate pathway known pathway lipoarabinomannan [9]. Isoprenoids synthesized            isoprenoid biosynthesis mycobacteria [19], pathways; mevalonate pathway                 unlikely case.  work using saturat-
present humans), non-mevalonate 1-deoxy-           ing transposon mutagenesis [20] gave rise predic-
D-xylulose 5-phosphate (DOXP) pathway,                 tion dxr essential gene. bacteria parasites. Genome
sequencing M. tuberculosis shown non-            order address question, used step
mevalonate pathway sole pathway present [3].        homologous recombination method attempt gener- pathway absent humans represents              ate defined mutant dxr M. tuberculosis [21]. dele-
attractive target drug development.                          tion delivery vector, pORTAL3- defined deletion                                                                  dxr, introduced M. tuberculosis single cross


                                                                                                                       Page 2 9
                                                                                               (page number citation purposes)
 BMC Microbiology 2008, 8:78                                                      http://www.biomedcentral.com/1471-2180/8/78



overs (SCOs) obtained. Double cross-overs (DCOs)               Resistance fosmidomycin efflux generated SCOs screened PCR               confirmed mycobacteria highly resistant determine wild type deletion allele            fosmidomycin resistance culture conditions. present. 40 DCOs screened               looked growth M. smegmatis M. tuberculosis
wild type, suggesting essentiality dxr.                          liquid medium presence fosmidomycin.                                                                     inhibition growth seen concentration unable isolate deletion mutant            1 mg/ml (Figure 2A & B), confirming species wild type background, constructed merodiploid                  resistant high level. dxr essential normal
strain carrying entire dxr operon native pro-          culture conditions Dxr sensitive fosmidomy-
moter mycobacteriophage L5 based integrating vec-              cin inhibition [1], explanation tor (pOPW: dxrintgm). DCOs generated                   high level resistance.
background screened PCR. 24
DCOs screened 12 deletion allele (50 ), indicat-            Resistance fosmidomycin attributed Fsr
ing able isolate chromosomal deletion            efflux pump micro-organisms [14,15]. Myco-
dxr background. expected genotype                  bacteria known posses efflux pumps number strains, termed "del-                 confer intrinsic antibiotic resistance [27-32]. investi-
inquents" e. deleted copy chromosome              gated efflux plays role fosmidomycin resist-
integrated, functional gene confirmed Southern               ance mycobacteria, utilising efflux pump
analysis (Figure 1B). data confirms dxr               inhibitors, reserpine, verapamil carbonyl cyanide m-
operon essential  complemented                 chlorophenylhydrazone (CCCP). concentrations operon).                                                      efflux pump inhibitors used taken previ-
                                                                    ous study M. smegmatis [27].  reserpine dxr operon (Figure 1A), possible      verapamil 12 40 μg/ml respectively inhib-
inability isolate mutants             itory growth.  CCCP concentration 15
downstream genes disrupted mutant. Analy-              μg/ml seen significantly inhibit growth M.
sis mutation created pORTAL3            smegmatis M. tuberculosis.  tested lower
delivery vector suggests disrupt promoter           concentrations CCCP; 1.25 μg/ml highest 
region start operon gene            mitted concentration growth rate notably
stream dxr (Rv2869c), non-essential intramembrane-             affected, inhibition seen.
cleaving protease (iCLIP) [22,23].
                                                                    Growth mycobacteria presence efflux pump order confirm dxr essential, used          inhibitors fosmidomycin assayed. cultures
gene switching strategy. relies fact efficient     grew OD 1.0 (approx 109 cell ml), indi-
replacement resident integrated vector easily           cating significant effects growth rate
achieved M. tuberculosis transformation selec-            final OD reached. difference sensitivity tion second integrating plasmid carrying different          species fosmidomycin seen presence
antibiotic resistance marker [24-26]. use            inhibitors, indicating efflux mecha-
delinquent strain carrying complete operon (pOPW)               nism resistance.
(dxrΔ, dxrint gm) tested ability plasmid carry-
ing operon dxr (pOPD; Figure 1A)                Transport fosmidomycin cells
complement chromosomal mutation. delinquent                 discounted efflux resistance mecha-
strain transformed pOPD plated                    nism, determined fosmidomycin trans-
hygromycin plates select incoming vector.             ported mycobacterial cells place.
hygromycin resistant transformants obtained,                   Uptake antibiotics typically measured using radi- control vector transformed cells          olabelled derivative.  radio-labelled fosmidomy-
efficiency 1.4 × 106per μg. contrast replacement           cin available commercially additional
pOPW pOPD wild-type background easily                   associated hazards connected using radio-isotopes
achieved efficiency 1.2 × 106 μg. data            Category level containment UK. indicate vector lacking dxr does comple-            microbiological bioassay, based inhibition E.
ment chromosomal mutation, dxr               coli active compounds, previously used itself essential. possible genes   measure fosmidomycin concentrations [11,33]. operon essential strategy         assay, active fosmidomycin measured inhibition future extended examining essentiality           E. coli growth disks. standard curve using known
genes operon.                                               concentrations fosmidomycin generated 


                                                                                                                         Page 3 9
                                                                                                 (page number citation purposes)
 BMC Microbiology 2008, 8:78                                                         http://www.biomedcentral.com/1471-2180/8/78




                           
                               Region deleted pORTAL3



                                          dxr             Rv2869c      gcpE           Rv2867c


                                Region deleted pOPD


                                                 Region present pOPW


                                                  Region present pOPD

                             (B)
               NotI                                                          NotI                wild-type
                                         probe

                                                         dxr          Rv2869c       gcpE          Rv2867c
                                        6.4 kb

               NotI                              NotI          NotI                              deletion
                                         probe

                                                         Rv2869c      gcpE           Rv2867c
                               4.0 kb




                                                           1 2           3

                                                                                      10 kb
                                   wt 6.4kb
                                                                                      6 kb
                                del 4.0 kb                                            4 kb
                                                                                      3 kb
                                 int 2.6 kb                                           2.5 kb




Figure 1
Demonstration   essentiality dxr
Demonstration essentiality dxr.   chromosomal location dxr operon, region deleted delivery vector (pORTAL3), regions present complementing vectors pOPW (complete operon) pOPD
(operon dxr) shown. (B) deletion delivery vector pORTAL3 introduced chromosome homol-
ogous recombination followed site-specific recombination complementing vector pOPW generate merodip-
loid strain. DCOs generated background analysed. Southern analysis representative DCOs isolated merodiploid background shown. Genomic DNA digested NotI hybridised indicated probe. sizes wild-type deletion alleles shown diagrammatically – replacement wild-type gene results additional NotI
site chromosome. Lane 1 – wild-type DCO (dxrwt, dxrint), Lane 2 – Deletion DCO (dxrΔ, dxrint), Lane 3 – markers. bands wild-type, deletion integrated copies dxr indicated.




                                                                                                                          Page 4 9
                                                                                                  (page number citation purposes)
 BMC Microbiology 2008, 8:78                                                    http://www.biomedcentral.com/1471-2180/8/78



                                                                  limit detection uptake assay 0.1 μg/
                                                                  ml, 10,000-fold level antibiotic                                                                   medium. limitations using high 
                                                                  centration fosmidomycin E. coli                                                                   antibiotic supernatant released
                                                                  cells antibiotic-induced lysis.                                                                    lead underestimate uptake, 
                                                                  estimate 

                                                                  Detoxification/modification
                                                                  results transport assay strongly suggested
                                                                  fosmidomycin resistance mycobacteria results
                                                                  lack active transport.  possi-
                                                                  ble tell antibiotic modified pre-
                                                                  vious assay. high concentration                                                                   antibiotic used; small proportion fos-
                                                                  midomycin modified,                                                                   detected loss fosmidomycin activity superna-
                                                                  tant.  possibility cells modify-
                                                                  ing antibiotic non-toxic form existed.                                                                   address question repeated exposure assay
                                                                  using lower concentration fosmidomycin                                                                   allowed precise quantification active antibi-
                                                                  otic supernatant. M. smegmatis E. coli cells                                                                   incubated 20 μg/ml fosmidomycin 60 min                                                                   active fosmidomycin assayed supernatant (Figure
                                                                  3B). supernatant exposed M. smegmatis, 2-fold
                                                                  reduction activity  20 10 μg/ml) seen.
Figure
Efflux
ance  2
       pump  inhibitors effect mycobacterial resist-
         fosmidomycin                                             Given limitation assay, difference
Efflux pump inhibitors effect mycobacte-               result change zone inhibition rial resistance fosmidomycin. Mycobacteria                1 mm, likely lack sensitivity grown presence 100 μg/ml fosmidomycin (Fos), 12         assay. addition, detoxification occurring μg/ml reserpine (RES), 40 μg/ml verapamil (VER) 1.25 μg/      expect complete reduction fosmidomy-
ml carbonyl cyanide m-chlorophenylhydrazone (CCCP)                cin activity. contrast 100-fold reduction fosmid- indicated.   M. tuberculosis grown 28 d       omycin activity seen E. coli supernatants  (B) M. smegmatis 16 h. Error bars represent standard          uptake extra-cellular environment deviation triplicate samples.
                                                                  cell).  modification antibiotic M. smeg-
                                                                  matis seen.

                                                                  fosmidomycin taken myco-
used quantify fosmidomycin  Additional file 1]             bacterial cells, intra-cellular enzymes
[34].                                                             capable detoxification. order address                                                                    determined extracts M. smegmatis capable
M. smegmatis, M. tuberculosis E. coli cells incu-        inactivating fosmidomycin. M. smegmatis cell-free
bated 1 mg/ml fosmidomycin 30 min (Figure             extracts incubated fosmidomycin (20 μg/ml
3A). Active fosmidomycin supernatant (extra-cellu-         200 μg/ml) 10 60 minutes. decrease fos-
lar) cell-free extracts (intra-cellular) measured.        midomycin activity seen time, indicating active fosmidomycin present cell-free               detoxifying enzymes present (Figure 4). extracts generated M. tuberculosis M. smegmatis;      data confirmed resistance modification fosmidomycin remained supernatant.           fosmidomycin.
trast, E. coli extracts contained 150 μg/ml reduction fosmidomycin super-           Discussion
natant seen. data confirmed fosmidomycin                Using step recombination process, demon-
uptake E. coli, conversely lack         strated Rv2870c (dxr) essential growth M.
uptake mycobacteria.                                           tuberculosis vitro. contradictory previous


                                                                                                                        Page 5 9
                                                                                                (page number citation purposes)
 BMC Microbiology 2008, 8:78                                                    http://www.biomedcentral.com/1471-2180/8/78




Figureof3fosmidomycin uptake
Assay
Assay fosmidomycin uptake. Uptake fosmidomycin measured mycobacteria E. coli. Cells subjected   1 mg/ml fosmidomycin 30 min; (B) 20 μg/ml fosmidomycin 60 min. Cell-free extracts (CFE) culture superna-
tants (SN) prepared serial dilutions applied paper disks described methods. assay, stand-
ard curve generated using known concentrations fosmidomycin. test samples, zones inhibition E. coli measured antibiotic concentration calculated standard curve.


reports TraSH analysis, predicted dxr         data dxr suggests prediction non-essen-
non-essential gene M. tuberculosis [20]. TraSH         tial incorrect, ratio obtained close predictions gene essentiality based ratio     cut point. data demonstrate generated microarray analysis transposon               case, able construct library, arbitrary cut point used distinguish     chromosomal deletion dxr merodiploid 
essential non-essential genes. closer inspection        ground.  able demonstrate


                                                                                                                       Page 6 9
                                                                                               (page number citation purposes)
 BMC Microbiology 2008, 8:78                                                     http://www.biomedcentral.com/1471-2180/8/78



                                                                   10  v/v OADC (7H10/OADC). M. smegmatis mc2155                                                                    grown Lemco media [39]. X-Gal (5-bromo-4-chloro-3-
                                                                   indolyl-β-D-galactopyranoside) used 50 μg/ml;
                                                                   IPTG (isopropyl-beta-D-thiogalactopyranoside) 0.5
                                                                   mM; kanamycin 20 μg/ml; hygromycin B 100 μg/ml;
                                                                   sucrose 2  w/v. Fosmidomycin (sodium salt)                                                                    purchased Invitrogen. Efflux pump inhibitors: reser-
                                                                   pine used 12 μg/ml; verapamil 40 μg/ml;                                                                    carbonyl cyanide m-chlorophenylhydrazone (CCCP)                                                                    1.25 μg/ml. M. tuberculosis growth curves conducted
                                                                   4 ml 7H9/Tw/OADC media 16 mm glass tubes
                                                                   containing 8 mm magnetic stirrer bar, stirring 150
                                                                   rpm.

                                                                   Attempt construct deletion mutants dxr
Figureof4fosmidomycin detoxification cell free extracts
Assay
                                                                   deletion delivery vector dxr (pORTAL3) 
Assay fosmidomycin detoxification cell free
extracts. Cell free extracts (CFE) tested inactiva-       structed follows (Figure 1): upstream flanking
tion fosmidomycin. Fosmidomycin, final assay concen-       region amplified M. tuberculosis genomic DNA
tration 20 200 μg/ml, incubated sterile 10 mM       using primer pair DXR F (PstI) 5'-TGGGCTGCAG-
Tris pH8 (control), M. smegmatis cell-free extract 10       CAACCCGCTAAGAAC-3, DXR Rev (NotI) 5'- 60 min. 100 μl aliquot test sample              CCCGCGGCCGCTTGATGCTAAGATGCCATGC-3' applied sterile paper disc aseptically placed media    downstream flanking region amplified using containing E. coli. diameter zone growth inhibi-     primer pair DXR DS F (NotI) 5'-CCCGCGGCCGCTGTTT-
tion measured. Error bars standard deviation        GTTACCGGCATTGTG-3' DXR DS Rev (HindIII) 5'-
triplicate samples.                                                CCCAAGCTTGGGCCAAGAAGAACCAGAAC-3'.                      Frag-
                                                                   ments cloned p2NIL (PstI-HindIII) using                                                                    underlined restriction sites. 6.3 kb PacI cassette dxr essential growth vitro,        pGOAL19 (hyg, sacB, lacZ) cloned sole
truly validated drug target needs proved essen-      PacI site. vector verified restriction digest tial vivo. Whilst extremely challenging [35],       sequencing. 5 μg UV pre-treated plasmid DNA [40] use inducible systems generating conditional                electroporated competent M. tuberculosis SCO
strains, recently described, allow           transformants selected 7H10/OADC medium
carried [36-38].                                               containing kanamycin hygromycin. DCOs iso-
                                                                   lated streaking cells plates lacking antibiotics Conclusion                                                         selected/screened media containing sucrose X- data demonstrate fosmidomycin taken             gal previously described [21]. PCR screening DCOs mycobacteria, resistance results intra-cel-        carried using primers DXR OL F (5'-TTGGACGA-
lular target inaccessible drug.         TAGATCGACACC-3') DXR OL Rev (5'-GATGGCATA-
validated dxr essential gene, possible   GATCAGCACCA-3'). prove useful drug target inhibitors enter cell developed. Alternatively fosmidomycin           complementing vector carrying entire dxr operon used conjunction compound                 native promoter constructed amplifying increases permeability. approaches involve             4.7 kb region genomic H37Rv DNA primers
nano-particulation fosmidomycin conversion            DXR OP C' F 5'-TTAATTAACACCTCGCGGTA-
fosmidomycin pro-drug, readily               CAGCTCGTC-3' DXR OP C' Rev 5'-TTAAT-
taken cell hydrolysed active            TAAGTCGTCAGCGCTGATATGCCC-3'. product form inside cell structure.                               cloned pSC (Stratagene); dxr_op/pSCA,                                                                    Gm-int cassette pUC-Gm-Int [41] intro-
Methods                                                            duced HindIII fragment pOPW (Figure 1).
Culture mycobacteria
M. tuberculosis H37Rv cultured Middlebrook 7H9              Construction merodiploid strain confirmation liquid medium supplemented 10  v/v OADC (oleic                essentiality
acid, bovine serum albumin, D-glucose, catalase; Becton            constructed merodiploid strain electroporating
Dickinson) 0.05   w/v Tween 80 (7H9/Tw/OADC)                   dxr SCO pOPW isolating kanamycin/hygro- solid Middlebrook 7H10 agar supplemented                mycin/gentamicin resistant transformants. DCOs 

                                                                                                                        Page 7 9
                                                                                                (page number citation purposes)
 BMC Microbiology 2008, 8:78                                                          http://www.biomedcentral.com/1471-2180/8/78



isolated PCR-screened  Strains            ducted experimental work, participated design
firmed Southern analysis using AlkPhos Direct sys-        drafted manuscript. authors read tem (GE Healthcare) label detect DNA. deletion          approved final manuscript.
derivative dxr_op/pSCA constructed 1.2 kb dxr gene removed site directed mutagenesis         Additional material primers DXR KO SDM F 5'-GTGACCAACTCGAC-
CGACGTATCTGGTATGGCTTCG-3' DXR KO SDM
Rev      5'-CGAAGCCATACCAGATACGTCGGTCGAGTT-                           Additional file 1
                                                                      Schematic representation bioassay used quantify fosmidomy-
GGTCAC-3'. Hyg-Int cassette pUC-Hyg-Int [41]                 cin. Cells exposed fosmidomycin; cell-free extracts culture fil- cloned HindIII digest. resulting plasmid,            trates prepared applied sterile paper discs. discs pOPD (Figure 1), used gene switching experi-                 aseptically placed media containing E. coli, test organism. ment [25]. Strains electroporated integrating               diameter zone growth inhibition measured following incuba-
vectors transformants isolated appropriate                 tion. Using known amounts fosmidomycin standard curve growth
                                                                      inhibition constructed used quantify fosmidomycin antibiotic selection  incoming vector). Transform-
                                                                      samples.
ants patch tested antibiotic resistance required.         Click file
                                                                      [http://www.biomedcentral.com/content/supplementary/1471-
Fosmidomycin uptake assays                                            2180-8-78-S1.tiff]
Bacteria grown late log phase (OD600 = 1.0,
approximately 109 cells ml), pelleted centrifugation 3 000 × g 5 minutes suspended 50 mM Tris
buffer pH 7.0 approximately 1011 cells ml. ml         Acknowledgements suspension added 0.5 ml fosmidomycin solu-             work funded EU Project QLRT-2001-00887 BBSRC
tion 3.5 ml LB media E. coli M. smegmatis         Project BB/D000181. like thank Karen Adie technical
                                                                 assistance, Paul Carroll manuscript suggestions Dean Crick val-
Middlebrook 7H9/Tw/OADC medium M. tuberculosis
                                                                 uable discussions. incubated 37°C 30 60 min shaking 100 rpm (E. coli, M. smegmatis) standing (M. tuberculo-
                                                                 References
sis). Cells pelleted centrifugation 3 000 × g     1.      Dhiman RK, Schaeffer ML, Bailey  Testa CA, Scherman H, Crick
5 minutes, supernatant collected, filter sterilized              DC: 1-Deoxy-D-Xylulose 5-Phosphate Reductoisomerase 0.2 μm syringe filter stored ice. Cells                 (IspC) Mycobacterium tuberculosis : 
                                                                         standing mycobacterial resistance fosmidomycin. J Bacte- washed twice 5 ml 50 mM Tris pH 7.0, sus-                riol 2005, 187(24):8395-8402.
pended 1 ml 10 mM Tris pH 7.0, transferred Fast       2.      Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC: Global bur-
                                                                         den tuberculosis. Estimated incidence, prevalence, Prep Lysing Matrix B tube (QBiogene) incubated                    mortality country. Journal American Medical Association 1999,
ice 5 min. Cell-free extracts prepared using                282:677-686.
Fast Prep speed 4 30 seconds (QBiogene). Samples          3.      Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, Gor-
                                                                         don SV, Eiglmeier K, Gas S, Barry CE, et al.: Deciphering biol- incubated ice 5 min, cell debris pelleted,               ogy Mycobacterium tuberculosis complete
cleared lysate recovered, filter sterilized stored ice.           genome sequence. Nature 1998, 393(6685):537-544.
                                                                 4.      Trias J, Jarlier V, Benz R: Porins cell wall mycobacteria.
                                                                         Science 1992, 258(5087):1479-1481.
Fosmidomycin quantitation                                        5.      Engelhardt H, Heinz C, Niederweis M: tetrameric porin limits
Fosmidomycin measured using microbiological                        cell wall permeability Mycobacterium smegmatis. J Biol
                                                                         Chem 2002, 277(40):37567-37572.
assay [34]. 100 ml cell-free extracts supernatants         6.      Mukhopadhyay S, Basu D, Chakrabarti P: Characterization  serial dilutions) applied sterile 14 mm filter            porin Mycobacterium smegmatis.                  J Bacteriol 1997,
paper disc (Whatman). discs allowed dry                   179(19):6205-6207.
                                                                 7.      Stephan J, Bender J, Wolschendorf F, Hoffmann C, Roth E, Mailander
room temperature 15 minutes transferral                  C, Engelhardt H, Niederweis M: growth rate Mycobacte-
individual 90 mm agar plates containing 0.5  v/v E.                rium smegmatis depends sufficient porin-mediated influx
                                                                         nutrients. Molecular Microbiology 2005, 58(3):714-730.
coli overnight culture. Plates incubated 20 hours       8.      Nguyen L, Thompson CJ: Foundations antibiotic resistance 37°C diameter zone bacterial growth                 bacterial physiology: mycobacterial paradigm. Trends inhibition measured. Discs known concentra-                     Microbiology 2006, 14(7):304-312.
                                                                 9.      Crick DC, Schulbach MC, Zink EE, Macchia M, Barontini S, Besra GS,
tions fosmidomycin used make standard                       Brennan PJ: Polyprenyl phosphate biosynthesis Mycobacte-
curve, calculate concentration fosmidomycin                 rium tuberculosis Mycobacterium smegmatis. J Bacteriol test solutions. concentration fosmidomycin                 2000, 182(20):5771-5778.
                                                                 10.     Kuzuyama T, Shimizu T, Takahashi S, Seto H: Fosmidomycin, samples calculated standard curve.                 specific inhibitor 1-deoxy-D-xylulose 5-phosphate reduc-
                                                                         toisomerase nonmevalonate pathway terpenoid
                                                                         biosynthesis. Tetrahedron Letters 1998, 39(43):7913-7916.
Authors' contributions                                           11.     Neu HC, Kamimura T: vitro vivo antibacterial activity
TP conceived study, participated design                FR-3 phosphonic acid antimicrobial agent. Antimicrob coordination drafted manuscript. ACB                     Agents Chemother 1564, 19(6):1013-1023.



                                                                                                                                   Page 8 9
                                                                                                          (page number citation purposes)
 BMC Microbiology 2008, 8:78                                                                        http://www.biomedcentral.com/1471-2180/8/78



12.   Neu HC, Kamimura T: Synergy fosmidomycin (FR-31564)                          Mycobacterium fortuitum. J Antimicrob Chemother 2006,
      antimicrobial agents. Antimicrob Agents Chemother                     57(2):252-259.
      1982, 22(4):560-563.                                                      33.   Cheoymang  Hudchinton D, Kioy D, Na-Bangchang K: Bioassay
13.   Sakamoto Y, Furukawa S, Ogihara H, Yamasaki M: Fosmidomycin                     determination fosmidomycin plasma urine:
      resistance adenylate cyclase deficient (cya) mutants                      Application pharmacokinetic dose optimisation. Journal       Escherichia coli. Biosci Biotechnol Biochem 2003, 67(9):2030-2033.              Microbiological Methods 2007, 69(1):65-69.
14.   Fujisaki S, Ohnuma S, Horiuchi T, Takahashi  Tsukui S, Nishimura Y,     34.   Kojo H, Shigi Y, Nishida M: FR-31564 new phosphonic acid
      Nishino T, Kitabatake M, Inokuchi H: Cloning gene                     antibiotic: bacterial resistance membrane permeability.
      Escherichia coli confers resistance fosmidomycin                   J Antibiot (Tokyo) 1980, 33(1):44-48.
      consequence amplification. Gene 1996, 175(1–2):83-87.                  35.   Thomson CJ, Power E, Ruebsamen-Waigmann H, Labischinski H:
15.   Halling SM, Peterson-Burch BD, Bricker BJ, Zuerner RL, Qing  Li L-            Antibacterial research development 21st Century
      L, Kapur V, Alt DP, Olsen SC: Completion genome                          – industry perspective challenges. Current Opinion       sequence Brucella abortus comparison highly                       Microbiology 2004, 7(5):445-450.
      similar genomes Brucella melitensis Brucella suis. J Bac-          36.   Blokpoel MCJ, Murphy HN, O'Toole R, Wiles S, Runn ESC, Stewart
      teriol 2005, 187(8):2715-2726.                            